SubsidieMeestersSpecific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
Projectdetails
Introduction
Cancer ranks as a major cause of death, with 3.4 million new incidences in 2020 in Europe. The current cancer standards of care include surgery, chemotherapy, radiotherapy, and, as of late, immunotherapy, none of which have met their expected therapeutic outcomes yet.
Photomedical Treatments
Photomedical treatments like photodynamic therapy of cancer (PDT) and Photochemical Internalisation (PCI) show great promise as effective anticancer treatments. Both are, however, limited by the cancer cells left behind, causing cancer recurrence and metastasis after recovering from their sublethal membrane injuries.
Proposed Solution
But what if we could label these injured cancer cells with antibodies, thus activating the immune system to eradicate them? SCALPEL will utilize PDT or PCI to destroy the bulk of tumour cells while marking the remaining sub-lethally damaged cancer cells for destruction by attaching antibodies to their membranes.
Administration of Components
Bespoke, modified SCALPEL components will be administered to all cells, normal and cancerous. Following local irradiation, only the photo-modified components will conjugate with our specially engineered antibodies, selectively flagging the cancer cells for destruction.
Immune System Training
Moreover, the immune system will be trained through this process against the specific cancers, offering systemic immunity.
Research Team
The high risk/high gain nature of SCALPEL is counterbalanced by an avant-garde, multidisciplinary research team, covering:
- Photomedicine/photobiology
- Immunology
- Synthetic chemistry
- Porphyrin chemistry
- Protein engineering
Expected Outcomes
SCALPEL is expected to revolutionize oncology by offering a pioneering photoimmunotherapy with curative potential. In this project, we strive to provide a proof-of-principle of the proposed technology in cell cultures, but also in laboratory animals, with the long-term vision of establishing SCALPEL as a clinical cancer modality.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 4.554.301 |
| Totale projectbegroting | € 4.554.301 |
Tijdlijn
| Startdatum | 1-3-2025 |
| Einddatum | 31-8-2029 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- OSLO UNIVERSITETSSYKEHUS HFpenvoerder
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
- PorphyChem
- KEMIJSKI INSTITUT
- INSTITUT GUSTAVE ROUSSY
- EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
From understanding to rational design of next-generation cancer therapiesThe project aims to enhance cancer treatment efficacy by combining immunotherapy with ultra-low dose therapies to exploit sublethal damage in tumor cells, improving tolerability and clinical outcomes. | ERC Advanced... | € 2.499.893 | 2022 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Breaching the protective cancer stroma with radiotherapy-responsive liposomesThis project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy. | ERC Starting... | € 1.942.158 | 2023 | Details |
An integrative genetic approach for the exploration of melanoma immunological interactionsThis project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses. | ERC Advanced... | € 2.500.000 | 2023 | Details |
From understanding to rational design of next-generation cancer therapies
The project aims to enhance cancer treatment efficacy by combining immunotherapy with ultra-low dose therapies to exploit sublethal damage in tumor cells, improving tolerability and clinical outcomes.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Breaching the protective cancer stroma with radiotherapy-responsive liposomes
This project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy.
An integrative genetic approach for the exploration of melanoma immunological interactions
This project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses.